Bcl-2 regulatory pathway is functional in chronic lymphocytic leukemia

Cytometry Part B - Clinical Cytometry

Volumn 63, Issue 1, 2005, Pages 36-46

  Goolsby, Charles ^a   Paniagua, Mary ^a   Tallman, Martin ^a   Gartenhaus, Ronald B ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

Author keywords

Apoptosis; B chronic lymphocytic leukemia; Bax; Bcl 2; Caspase activation; Flow cytometry

Indexed keywords

CASPASE; CASPASE 3; CASPASE 8; CASPASE 9; CD23 ANTIGEN; CD5 ANTIGEN; LIPOCORTIN 5; PROTEIN BAX; PROTEIN BCL 2;

ADULT; AGED; APOPTOSIS; ARTICLE; AUTOCRINE EFFECT; B LYMPHOCYTE; CELL PROLIFERATION; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME ACTIVATION; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MEMBRANE POTENTIAL; MITOCHONDRIAL MEMBRANE; PARACRINE SIGNALING; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FAMILY; T LYMPHOCYTE; UPREGULATION;

AGED; ANNEXIN A5; APOPTOSIS; B-LYMPHOCYTES; BCL-2-ASSOCIATED X PROTEIN; CASPASES; CELL COUNT; CELLS, CULTURED; FEMALE; FLOW CYTOMETRY; HUMANS; IMMUNOPHENOTYPING; LEUKEMIA, LYMPHOCYTIC, CHRONIC; MALE; MEMBRANE POTENTIALS; MIDDLE AGED; MITOCHONDRIA; PROTO-ONCOGENE PROTEINS C-BCL-2;

EID: 11844301367     PISSN: 15524949     EISSN: None     Source Type: Journal    
DOI: 10.1002/cyto.b.20034     Document Type: Article

References (79)

1. Dighiero G, Travade P, Chevret S, et al. B-cell chronic lymphocytic leukemia: present status and future directions. French Cooperative Group on CLL. Blood 1991;78:1901-1914.
2. O'Brien S, del Giglio A, Keating M. Advances in the biology and treatment of B-cell chronic lymphocytic leukemia. Blood 1995;85:307-318.
3. Lee JS, Dixon DO, Kantarjian HM, et al. Prognosis in chronic lymphocytic leukemia: a multivariate regression analysis of 325 untreated patients. Blood 1987;69:929-936.
4. Parker SL, Tong T, Bolden S, Wingo PA. Cancer statistics, 1997. CA Cancer J Clin 1997;47:5-27.
5. Finn WG, Thangavelu M, Yelavarthi KK, et al. Karyotype predicts morphology and immunophenotype in chronic lymphocytic leukemia (CLL). Am J Clin Pathol 1996;105:458-467.
6. Moreau EJ, Matutes E, A'Hern RP, et al. Improvement of the chronic lymphocytic leukemia scoring system with the monoclonal antibody SN8 (CD79b). Am J Clin Pathol 1997;108:378-382.
7. Domingo A, Gonzalez-Barca E, Castellsague X, et al. Expression of adhesion molecules in 113 patients with B-cell chronic lymphocytic leukemia: relationship with clinico-prognostic features. Leuk Res 1997;21:67-73.
8. Lucio PJ, Faria MT, Pinto AM, et al. Expression of adhesion molecules in chronic B-cell lymphoproliferative disorders. Haematology 1998;8:104-111.
9. Damle RN, Wasil T, Fais F, et al. Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia. Blood 1999;94:1840-1847.
10. Juliusson G, Merup M. Cytogenetics in chronic lymphocytic leukemia. Semin Oncol 1998;25:19-26.
11. Dohner H, Stilgenbauer S, Benner A, et al. Genomic aberrations and survival in chronic lymphocytic leukemia. N Engl J Med 2000;343:1910-1916.
12. Que TH, Marco JG, Ellis J, et al. Trisomy 12 in chronic lymphocytic leukemia detected by fluorescence in situ hybridization: analysis by stage, immunophenotype, and morphology. Blood 1993;82:571-575.
13. Starostik P, O'Brien S, Chung C-Y, et al. The prognostic significance of 13q14 deletions in chronic lymphocytic leukemia. Leuk Res 1999;23:795.
14. Tabernero MD, San Miguel JF, Garcia JL. Clinical, biological, and immunophenotypical characteristics of B-cell chronic lymphocytic leukemia with trisomy 12 by fluorescence in situ hybridization. Cytometry 1995;22:217-222.
15. Dohner H, Fischer K, Bentz M, et al. p53 Gene deletion predicts poor survival and non-response to therapy with purine analogs in chronic B-cell leukemias. Blood 1995;85:1580-1589.
16. Gaidano GL, Ballerini P, Gong JZ, et al. p53 Mutations in human lymphoid malignancies: association with Burkitt lymphoma and chronic lymphocytic leukemia. Proc Natl Acad Sci USA 1991;88:5413-5417.
17. Lens D, Dyer MJ, Garcia-Marco JM, et al. p53 Abnormalities in CLL are associated with excess of prolymphocytes and poor prognosis. Br J Haematol 1997;99:848-857.
18. Dohner H, Stilgenbauer S, James MR, et al. 11q Deletions identify a new subset of B-cell chronic lymphocytic leukemia characterized by extensive nodal involvement and inferior prognosis. Blood 1997;89:2516-2522.
19. Dohner H, Stilgenbauer S, Doner K, et al. Chromosome aberrations in B-cell chronic lymphocytic leukemia: Reassessment based on molecular genetic analysis. J Mol Med 1999;77:266-281.
20. Andreeff M, Darzynkiewicz A, Sharpless TK, et al. Discrimination of human leukemia subtypes by flow cytometric analysis of cellular DNA and RNA. Blood 1980;55:282-293.
21. Hanada M, Delia D, Aiello A, et al. Bcl-2 gene hypomethylation and high-level expression in B-cell chronic lymphocytic leukemia. Blood 1993;82:1820-1828.
22. Hoffbrand AV, Panayiotidis P, Reittie J, Ganeshaguru K. Autocrine and paracrine growth loops in chronic lymphocytic leukemia. Semin Hematol 1993;30:306-317.
23. McConkey DJ, Chandra J, Wright S, et al. Apoptosis sensitivity in chronic lymphocytic leukemia is determined by endogenous endonuclease content and relative expression of bcl-2 and bax. J Immunol 1996;156:2624-2630.
24. Pepper C, Bentley P, Hoy T. Regulation of clinical chemoresistance by bcl-2 and bax oncoproteins in B-cell chronic lymphocytic leukaemia. Br J Haematol 1996;95:513-517.
25. Pepper C, Hoy T, Bentley DP. Bcl-2/bax ratios in chronic lymphocytic leukaemia and their correlation with in vitro apoptosis and clinical resistance. Br J Cancer 1997;76:935-938.
26. Robertson LE, Plunkett W, McConnell K, et al. Bcl-2 expression in chronic lymphocytic leukemia and its correlation with the induction of apoptosis and clinical outcome. Leukemia 1996;10:456-459.
27. Thomas A, El Rouby S, Reed JC, et al. Drug-induced apoptosis in B-cell chronic lymphocytic leukemia: relationship between p53 gene mutation and bcl-2/bax proteins in drug resistance. Oncogene 1996;12:1055-1062.
28. Delmer A, Ajchenbaum-Cymbalista F, Tang R, et al. Overexpression of cyclin D2 in chronic B cell malignancies. Blood 1995;85:2870-2876.
29. Gottardi D, Alfarano A, De Leo AM, et al. Defective apoptosis due to bcl-2 Overexpression may explain why CLL cells accumulate in GO. Curr Top Microbiol Immunol 1995;194:307-312.
30. Kornblau SM, Chen N, del Giglio A, et al. Retinoblastoma protein expression is frequently altered in chronic lymphocytic leukemia. Cancer Res 1994;54:242-246.
31. Kip1 in chronic B-cell lymphocytic leukemia. Blood 1998;91:4694-4700.
32. + B cells the expression of BCL-2 gene family is shifted toward protection from apoptosis. Br J Haematol 1996;94:612-618.
33. Schena M, Larsson LG, Gottardi D, et al. Growth- and differentiation- associated expression of bcl-2 in B-chronic lymphocytic leukemia cells. Blood 1992;79:2981-2989.
34. Kitada S, Andersen J, Akar S, et al. Expression of apoptosis-regulating proteins in chronic lymphocytic leukemia: Correlations with in vitro and in vivo chemoresponses. Blood 1998;91:3379-3389.
35. Begleiter A, Mowat M, Israels LG, Johnston JB. Chlorambucil in chronic lymphocytic leukemia: Mechanism of action. Leuk Lymphoma 1996;23:187-201.
36. Byrd JC, Shinn C, Waselenko JK, et al. Flavopiridol induces apoptosis in chronic lymphocytic leukemia cells via activation of caspase-3 without evidence of bcl-2 modulation or dependence on functional p53. Blood 1998;92:3804-3816.
37. Lambrechts AC, Hupkes PE, Dorssers LCJ, van't Veer MB. Translocation (14;18)-positive cells are present in the circulation of the majority of patients with localized (stage I and II) follicular non-Hodgkin's lymphoma. Blood 1993;82:2510-2516.
38. Soubeyran P, Cabanillas F, Lee MS. Analysis of the expression of the hybrid gene bcl-2/IgH in follicular lymphoma. Blood 1993;81:122-127.
39. Moriano MT, Moretti L, Donelli A, et al. Bcl-2 gene expression in hematopoietic cell differentiation. Blood 1992;80:768-775.
40. Collins RJ, Vershuer LA, Harmon BV, Prentice RL, Pope JH, Kerr JFR. Spontaneous programmed death (apoptosis) of B-chronic lymphocytic leukaemia cells following their culture in vitro. Br J Haematol 1989;71:343-350.
41. Robertson LE, Plunkett W. Apoptotic cell death in chronic lymphocytic leukemia. Leuk Lymphoma 1993;11:71-74.
42. Panayiotidis P, Jones D, Ganeshaguru K, et al. Human bone marrow stromal cells prevent apoptosis and support the survival of chronic lymphocytic leukaemia cells in vitro. Br J Haematol 1996;92:97-103.
43. Lagneaux L, Delforge A, Bron D, et al. Chronic lymphocytic leukemic B cells but not normal B cells are rescued from apoptosis by contact with normal bone marrow stromal cells. Blood 1998;91:2387-2396.
44. Vincent AM, Cawley JC, Burthem J. Integrin function in chronic lymphocytic leukemia. Blood 1996;87:4780-4788.
45. Csanaky G, Matutes E, Vass JA, et al. Adhesion receptors on peripheral blood leukemic B cells: a comparative study on B cell chronic lymphocytic leukemia and related lymphoma/leukemias. Leukemia 1997;11:408-415.
46. Molica S, Dattilo A, Mannella A, Levato D. Intercellular adhesion molecules (ICAMs) 2 and 3 are frequently expressed in B cell chronic lymphocytic leukemia. Leukemia 1996;10:907-908.
47. Behr SI, Korinth D, Schriever F. Differential adhesion pattern of B cell chronic lymphocytic leukemia cells. Leukemia 1998;12:71-77.
48. Suut L, O'Connor SJM, Richards SJ, et al. Trisomy 12 is seen within a specific subtype of B-cell chronic lymphoproliferative disease affecting the peripheral blood/bone marrow and co-segregates with elevated expression of CD11a. Br J Haematol 1998;101:165-170.
49. Burger JA, Tsukada N, Burger M, et al. Blood derived nurse-like cells protect chronic lymphocytic leukemia B cells from spontaneous apoptosis through stromal cell-derived factor-1. Blood 2000;96:2655-2263.
50. Trentin L, Zambello R, Agostini C, et al. Expression and regulation of tumor necrosis factor, interleukin-2, and hematopoietic growth factor receptors in B-cell chronic lymphocytic leukemia. Blood 1994;84:4249-4256.
51. van Kooten C, Rensink I, Aarden L, van Oers R. Interleukin-4 inhibits both paracrine and autocrine tumor necrosis factor-α-induced proliferation of B chronic lymphocytic leukemia cells. Blood 1992;80:1299-1306.
52. Caligaris-Cappio F, Hamblin TJ. B-cell chronic lymphocytic leukemia: a bird of a different feather. J Clin Oncol 1999;17:399-408.
53. Castejon R, Vargas JA, Romero Y, et al. Modulation of apoptosis by cytokines in B-cell chronic lymphocytic leukemia. Commun Clin Cytometry 1999:38:224-230.
54. Dancescu M, Rubio-Trujillo M, Biron G, et al. Interleukin 4 protects chronic lymphocytic leukemic B cells from death by apoptosis and upregulates Bcl-2 expression. J Exp Med 1992;176:1319-1326.
55. Mainou-Fowler T, Copplestone JA, Prentice AG. Effect of interleukins on the proliferation and survival of B cell chronic lymphocytic leukaemia cells. J Clin Pathol 1995;48:482-487.
56. Mainou-Fowler T, Prentice AG. Modulation of apoptosis with cytokines in B-cell chronic lymphocytic leukaemia. Leuk Lymphoma 1996;21:369-377.
57. Panayiotidis P, Ganeshaguru K, Jabbar SAB, Hoffbrand AV. Interleukin-4 inhibits apoptotic cell death and loss of the bcl-2 protein in B-chronic lymphocytic leukaemia cells in vitro. Br J Haematol 1993;85:439-445.
58. Reittie JE, Hoffbrand AV. Interleukin-4 (IL-4) inhibits proliferation and spontaneous cytokine release by chronic lymphocytic leukaemia cells. Leuk Res 1994;18:55-60.
59. Buschle M, Campana D, Carding SR, et al. Interferon-γ inhibits apoptotic cell death in B-cell chronic lymphocytic leukaemia. J Exp Med 1993;177:213-218.
60. Panayiotidis P, Ganeshaguru K, Jabbar SAB, Hoffbrand AV. Alpha-interferon (α-IFN) protects B-chronic lymphocytic leukaemia cells from apoptotic cell death in vitro. Br J Haematol 1994;86:169-173.
61. Chaouchi N, Wallon C, Goujard C, et al. Interleukin-13 inhibits interleukin-2-induced proliferation and protects chronic lymphocytic leukemia B cells from in vitro apoptosis. Blood 1996;87:1022-1029.
62. Goolsby CL, Steiner M, Nemeth J. Viral and cellular oncogene expression during progressive malignant transformation of SV40 transformed human fibroblasts. Cytometry 1991;12:748-756.
63. Gilmore K, Wilson M. The use of chloromethyl-X-rosamine (mitotracker red) to measure loss of mitochondrial membrane potential in apoptotic cells is incompatible with cell fixation. Cytometry 1999;36:355-358.
64. Wickremasinghe RG, Hoffbrand AV. Biochemical and genetic control of apoptosis: relevance to normal hematopoiesis and hematological malignancies. Blood 1999;93:3587-3600.
65. Krajewski S, Gascoyne RD, Zapata JM, et al. Immunolocalization of the ICE/Ced-3-family protease, CPP32 (caspase-3), in non-Hodgkin's lymphomas (NHLs), chronic lymphocytic leukemias (CLL), and reactive lymph nodes. Blood 1997;89:3817-3825.
66. Bartik MM, Welker D, Kay NE. Impairments in immune cell function in B cell chronic Iymphocytic leukemia. Semin Oncol 1998;25:27-33.
67. Mu X, Kay NE, Gosland MP, Jennings CD. Analysis of blood T-cell cytokine expression in B-chronic lymphocytic leukaemia: evidence for increased levels of cytoplasmic IL-4 in resting and activated CD8 T cells. Br J Haematol 1997;96:733-735.
68. Decker T, Flohr T, Trautmann P, et al. Role of accessory cells in cytokine production by T cells in chronic B-cell lymphocytic leukemia. Blood 1995;86:1115-1123.
69. Craig VA, Mainou-Fowler T, Prentice AG. Effect of interleukin-4 (IL-4) and dexamethasone and bcl-2 expression in B-chronic lymphocytic leukaemia (CLL) in culture [abstract]. Exp Hematol 1993;21:1090.
70. Collins DP. Receptors for cytokine and growth factors on CLL lymphocytes. In: Marti GE, Vogt RF, Zenger VE, editors. Determining the role of environmental exposures as risk factors for B-cell lymphopro-liferative disorders. Atlanta: US Department of Health and Human Services; 1997. p 107-112.
71. Douglas RS, Capocasale RJ, Lamb RJ, et al. Chronic lymphocytic leukemia B cells are resistant to the apoptotic effects of transforming growth factor-β. Blood 1997;89:941-947.
72. + T-cell population. Commun Clin Cytometry 2000;42:188-195.
73. Farace F, Orlanducci F, Dietrich PY, et al. T cell repertoire in patients with B chronic lymphocytic leukemia. Evidence for multiple in vivo T cell clonal expansions. J Immunol 1994;153:4281-4290.
74. Rezvany MR, Jeddi-Tehrani M, Osterborg A, et al. Oligoclonal TCRBV gene usage in Bcell chronic lymphocytic leukemia: major perturbations are preferentially seen within the CD4 T-cell subset. Blood 1999;94:1063-1069.
75. + T cell subsets in chronic lymphocytic leukemia. J Immunol 1997;158:1482-1489.
76. Wen T, Melistedt H, Jondal M. Presence of clonal T cell populations in chronic B lymphocytic leukemia and smoldering myeloma. J Exp Med 1990;171:659-666.
77. Hoffbrand AV, Panayiotidis P, Reittie J, Ganeshaguru K. Autocrine and paracrine growth loops in crhonic lymphocytic leukemia. Semin Hematol 1993;30:306-317.
78. Pistoia V. Production of cytokines by human B cells in health and disease. Immunol Today 1997;18:343-350.
79. Lotz M, Ranheim E, Kipps TJ. Transforming growth factor β as endogenous growth inhibitor of chronic lymphocytic leukemia B cells. J Exp Med 1994;179:999-1004.